Toru Ichinose
Nagoya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy.
Journal: Molecular oncology
Published: October 12, 2023
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Journal: Nagoya journal of medical science
Published: November 16, 2020
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment.
Journal: International journal of cancer
Published: September 17, 2020
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth.
Journal: Molecular therapy oncolytics
Published: October 09, 2018
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Journal: Cancers
Published: July 18, 2018
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Journal: BMC cancer
Published: November 13, 2017
Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.
Journal: Frontiers in oncology
Published: April 28, 2017
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.
Journal: Oncolytic virotherapy
Published: March 24, 2017
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Journal: International journal of cancer
Published: April 02, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026